Premium
Emerging therapies in immunoglobulin A nephropathy
Author(s) -
Yeo See Cheng,
Liew Adrian,
Barratt Jonathan
Publication year - 2015
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12527
Subject(s) - medicine , immunosuppression , immunology , pathogenesis , clinical trial , disease , nephropathy , bioinformatics , pathology , biology , diabetes mellitus , endocrinology
Despite advances in our understanding of immunoglobulin A nephropathy ( IgAN ) over the past decade, there are currently no specific therapies capable of targeting key pathways involved in the pathogenesis of the disease. Recent studies have, however, provided new insights into important molecular pathways that are likely to be amenable to therapeutic manipulation in the future. Specifically, a deeper understanding of the role of mucosal immunity, B ‐cell activation and mesangial cell activation in IgAN has provided the impetus for a number of exciting phase II / III clinical trials in IgAN . In this review, we examine some of these on‐going studies, first examining studies that clarify the role of traditional immunosuppression in IgAN , then focusing on novel therapies in early clinical studies, looking closely at the rationale for these agents in relation to our current understanding of the pathogenesis of IgAN . Finally, we examine emerging pathways and therapeutic agents that have the potential to be developed as novel therapies in the coming years. It is hoped that as we continue to develop a greater understanding of IgAN , emerging therapies will soon become a reality in the day‐to‐day treatment of patients with IgAN .